BDTX-1535 Goes after Osimertinib Resistance

Area of Science:

• Oncology
• Pharmacology
• Neuro-oncology

Background:

• Osimertinib is a standard treatment for EGFR-mutant non-small cell lung cancer (NSCLC).
• Resistance to osimertinib remains a significant clinical challenge in NSCLC treatment.
• Glioblastoma (GBM) is an aggressive primary brain tumor with limited treatment options.

Purpose of the Study:

• To evaluate the potential of BDTX-1535, an investigational tyrosine kinase inhibitor, in overcoming osimertinib resistance in EGFR-mutant NSCLC.
• To assess the preclinical efficacy of BDTX-1535 in treating central nervous system (CNS) metastases, specifically in glioblastoma models.

Main Methods:

• Preclinical studies were conducted to assess the activity of BDTX-1535.
• The in vitro and in vivo models included EGFR-mutant NSCLC cell lines with acquired resistance to osimertinib.
• Glioblastoma models were utilized to evaluate CNS efficacy.

Main Results:

• BDTX-1535 demonstrated the potential to mitigate or overcome resistance to osimertinib in preclinical models of EGFR-mutant NSCLC.
• The investigational agent showed preclinical efficacy in glioblastoma models, suggesting potential for treating CNS metastases.

Conclusions:

• BDTX-1535 represents a potential therapeutic strategy for patients with EGFR-mutant NSCLC who develop resistance to osimertinib.
• The drug's efficacy in preclinical brain tumor models warrants further investigation for CNS-targeted therapy in lung cancer patients with brain metastases.